Researchers track how real patients fare on two leading kidney cancer treatments
NCT ID NCT06345183
Summary
This study looked back at the medical records of 327 adults with advanced kidney cancer to see how they fared in everyday medical practice. It compared two different combination drug treatments: Nivolumab with Ipilimumab, and Pembrolizumab with Lenvatinib. The goal was to understand patient characteristics, how the treatments were used, and what the real-world outcomes were, not to test a new cure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RENAL CELL CARCINOMA (ARCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cardinal Health
Dublin, Ohio, 43017, United States
Conditions
Explore the condition pages connected to this study.